4/18
10:22 am
mrk
Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.
Low
Report
Merck & Co., Inc. (NYSE: MRK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $135.00 price target on the stock.
4/17
09:18 pm
mrk
Wealth Of Korea's 50 Richest On Forbes List Rises To $115 Billion [Forbes]
Low
Report
Wealth Of Korea's 50 Richest On Forbes List Rises To $115 Billion [Forbes]
4/17
07:39 pm
mrk
Merck (MRK) Advances While Market Declines: Some Information for Investors [Yahoo! Finance]
Low
Report
Merck (MRK) Advances While Market Declines: Some Information for Investors [Yahoo! Finance]
4/17
04:48 pm
mrk
Korea's 50 Richest 2024: AI Frenzy Boosts Combined Wealth To $115 Billion [Forbes]
Low
Report
Korea's 50 Richest 2024: AI Frenzy Boosts Combined Wealth To $115 Billion [Forbes]
4/17
04:05 pm
mrk
Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To [Seeking Alpha]
Low
Report
Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To [Seeking Alpha]
4/15
08:50 am
mrk
NCCN Foundation Announces Recipients for 2024 Young Investigator Awards Honoring Future Leaders of Cancer Research [Yahoo! Finance]
Low
Report
NCCN Foundation Announces Recipients for 2024 Young Investigator Awards Honoring Future Leaders of Cancer Research [Yahoo! Finance]
4/14
05:43 am
mrk
Merck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish. [Yahoo! Finance]
Low
Report
Merck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish. [Yahoo! Finance]
4/12
08:51 am
mrk
1 New Green Flag for Moderna and Merck Stock [Yahoo! Finance]
Low
Report
1 New Green Flag for Moderna and Merck Stock [Yahoo! Finance]
2/1/2024
06:30 am
mrk
merck & company, inc. (new)
BEAT
Report
4.7%
merck & company, inc. (new)
10/26/2023
06:30 am
mrk
merck & company, inc. (new)
BEAT
Report
1.5%
merck & company, inc. (new)
8/1/2023
06:30 am
mrk
merck & company, inc. (new)
MISS
Report
-1.3%
merck & company, inc. (new)
4/27/2023
06:30 am
mrk
merck & company, inc. (new)
BEAT
Report
0.1%
merck & company, inc. (new)
4/11
04:13 pm
mrk
Form ARS Merck & Co., Inc. For: Dec 31
Low
Report
Form ARS Merck & Co., Inc. For: Dec 31
4/11
04:11 pm
mrk
Form DEFA14A Merck & Co., Inc.
Low
Report
Form DEFA14A Merck & Co., Inc.
4/11
04:09 pm
mrk
Form DEF 14A Merck & Co., Inc. For: May 28
Low
Report
Form DEF 14A Merck & Co., Inc. For: May 28
4/11
04:06 pm
mrk
Form 10-K/A Merck & Co., Inc. For: Dec 31
Low
Report
Form 10-K/A Merck & Co., Inc. For: Dec 31
4/8
01:56 pm
mrk
Form 3 Merck & Co., Inc. For: Apr 01 Filed by: Larson Betty D
Low
Report
Form 3 Merck & Co., Inc. For: Apr 01 Filed by: Larson Betty D
4/1
05:17 pm
mrk
Form PX14A6G Merck & Co., Inc. Filed by: Inspire Investing, LLC
Low
Report
Form PX14A6G Merck & Co., Inc. Filed by: Inspire Investing, LLC
3/29
04:19 pm
mrk
Form 4 Merck & Co., Inc. For: Mar 28 Filed by: WENDELL PETER C
Low
Report
Form 4 Merck & Co., Inc. For: Mar 28 Filed by: WENDELL PETER C
3/29
04:17 pm
mrk
Form 4 Merck & Co., Inc. For: Mar 28 Filed by: Seidman Christine E
Low
Report
Form 4 Merck & Co., Inc. For: Mar 28 Filed by: Seidman Christine E
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd lot
Avg. bid-ask spread
Avg. bid-ask size
Shares at ask/bid
Off exchange
Main News & Impact Reports
3/28
Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies
7.5%
3/25
Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response
6.5%
3/3
Form 4 Merck & Co., Inc. For: Feb 28 Filed by: Fleming Michael
6.1%
3/2
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
5.6%
3/17
Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough
5.3%
4/1
Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic
4.2%
4/27
UPDATE 1-Neurocrine gets U.S. approval for Parkinson's therapy, COVID-19 delays launch [Reuters]
3.4%
10/28
Merck wins second chance to arbitrate rotavirus vaccine antitrust case [Reuters]
3.3%
10/3
Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates [Investor's Business Daily]
2.7%
1/31
Bristol-Myers pulls Opdivo+Yervoy lung application in Europe [Reuters]
2.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Register